Keyword: ARCH Venture Partners
Now, Insitro is ready to share a little more—starting with a Gilead partnership worth $15 million upfront, but that could total more than $1 billion.
The goal is to genetically modify and differentiate stem cells to create cell therapies that are cloaked from the immune system.
Maze Therapeutics aims to understand how some genes provide protection against disease so that they can be targeted with drugs.
HiberCell reckons it is the first to exclusively focus on detecting and treating tumor dormancy that can lead to cancer spread.
Glympse Bio, a startup that builds bioengineered in vivo sensors for disease, has emerged from stealth with a $22 million series A round.
The appointment puts the Sage and Voyager co-founder in charge of advancing a muscarinic agonist he worked on at Eli Lilly in the 1990s.
Mindstrong Health rounded up $15 million in series B financing to continue development of its mental health-tracking smartphone app.
Alta Partners raised $130 million for its ninth venture capital fund, focusing on biotech and healthcare technology companies.
Metacrine raised $65 million to launch phase 1 testing of its FXR agonist in NASH and gastrointestinal diseases later this month.
Brii Biosciences' mission is to overcome the challenges that have prevented the spread of innovative medicines throughout China.